First seen Jul 1, 2026 · Updated 19h ago · 2 source items
Newly presented real-world outcomes data for approved Alzheimer's therapies is fueling disagreement between clinical and investor communities.
Real-world effect sizes drive payer coverage decisions and long-term franchise value.
Moderate expected market impact (relevance 72/100). Most exposed: $BIIB, $LLY.
The real-world discontinuation rates in this registry are double the trial rates. That is the number payers will anchor on.
♥ 1.6K⇄ 490💬 270👁 233.0K
Registry data complicates Alzheimer's therapy outlook
New registry results show higher discontinuation and mixed effectiveness versus pivotal trials.
2d ago · BioPharma Ledger
Registry data complicates Alzheimer's therapy outlook
23h ago · X
The real-world discontinuation rates in this registry are double the trial rates. That is the number payers will anchor on.
Moderate confidence (70/100), supported mainly by source credibility (68) and limited mainly by engagement depth (50).
Tickers
Topics
Registry populations differ systematically from trial populations; direct comparison overstates the gap.